Skip to main content

Advertisement

SpringerLink
Log in

The role of antiangiogenesis therapy: Bevacizumab and beyond

  • Educational Series
  • Molecular Targets in Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of angiogenesis, is associated with poor prognosis in cancer. As a result, several therapeutic agents that inhibit the actions of VEGF or its receptors are currently in development for use in advanced solid tumours, such breast, colorectal, lung and renal cancer. Clinical data from trials of anti-VEGF agents in this group of tumours are discussed, with a particular focus on the efficacy and safety of bevacizumab, the anti-VEGF agent at the most advanced stage of development in those tumour types. Future potential uses of bevacizumab in cancer therapy will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Winer EP, Morrow M, Osborne CK, Harris JR (2001) Malignant tumors of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Williams and Wilkins, Philadelphia, pp 651–717

    Google Scholar 

  2. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410

    Article  PubMed  CAS  Google Scholar 

  3. Marty M, Pivot X (2008) The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer 44:912–920

    Article  PubMed  CAS  Google Scholar 

  4. Jain RK (2002) Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 29:3–9

    PubMed  CAS  Google Scholar 

  5. Achen MG, Stacker SA (1998) The vascular endothelial growth factor family; proteins which guide the development of the vasculature. Int J Exp Pathol 79:255–265

    Article  PubMed  CAS  Google Scholar 

  6. Gerwins P, Skoldenberg E, Claesson-Welsh L (2000) Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 34:185–194

    Article  PubMed  CAS  Google Scholar 

  7. Houck KA, Ferrara N, Winer J et al (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806–1814

    Article  PubMed  CAS  Google Scholar 

  8. Tischer E, Mitchell R, Hartman T et al (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947–11954

    PubMed  CAS  Google Scholar 

  9. Ferrara N (1999) Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56:794–814

    Article  PubMed  CAS  Google Scholar 

  10. Tuder RM, Flook BE, Voelkel NF (1995) Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 95:1798–1807

    Article  PubMed  CAS  Google Scholar 

  11. Petit AM, Rak J, Hung MC et al (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523–1530

    PubMed  CAS  Google Scholar 

  12. Ikeda E, Achen MG, Breier G, Risau W (1995) Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270:19761–19766

    Article  PubMed  CAS  Google Scholar 

  13. Rak J, Mitsuhashi Y, Bayko L et al (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55:4575–4580

    PubMed  CAS  Google Scholar 

  14. Bouvet M, Ellis LM, Nishizaki M et al (1998) Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 58:2288–2292

    PubMed  CAS  Google Scholar 

  15. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671–674

    Article  PubMed  CAS  Google Scholar 

  16. de Vries C, Escobedo JA, Ueno H et al (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989–991

    Article  PubMed  Google Scholar 

  17. Terman BI, Dougher-Vermazen M, Carrion ME et al (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187:1579–1586

    Article  PubMed  CAS  Google Scholar 

  18. Folkman J, Cole P, Zimmerman S (1966) Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 164:491–502

    Article  PubMed  CAS  Google Scholar 

  19. Borgstrom P, Gold DP, Hillan KJ, Ferrara N (1999) Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19:4203–4214

    PubMed  CAS  Google Scholar 

  20. Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844

    Article  PubMed  CAS  Google Scholar 

  21. von Marschall Z, Cramer T, Hocker M et al (2000) De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 119:1358–1372

    Article  Google Scholar 

  22. Neufeld G, Kessler O, Vadasz Z, Gluzman-Poltorak Z (2001) The contribution of proangiogenic factors to the progression of malignant disease: role of vascular endothelial growth factor and its receptors. Surg Oncol Clin N Am 10:339–356

    PubMed  CAS  Google Scholar 

  23. Gabrilovich D, Ishida T, Oyama T et al (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:4150–4166

    PubMed  CAS  Google Scholar 

  24. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676

    Article  PubMed  CAS  Google Scholar 

  25. Inai T, Mancuso M, Hashizume H et al (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165:35–52

    PubMed  CAS  Google Scholar 

  26. Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–147

    Article  PubMed  CAS  Google Scholar 

  27. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989

    Article  PubMed  CAS  Google Scholar 

  28. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62

    Article  PubMed  CAS  Google Scholar 

  29. Wildiers H, Guetens G, De Boeck G et al (2003) Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88:1979–1986

    Article  PubMed  CAS  Google Scholar 

  30. Baluk P, Hashizume H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15:102–111

    Article  PubMed  CAS  Google Scholar 

  31. Osusky KL, Hallahan DE, Fu A et al (2004) The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7:225–233

    Article  PubMed  CAS  Google Scholar 

  32. Vosseler S, Mirancea N, Bohlen P et al (2005) Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 65:1294–1305

    Article  PubMed  CAS  Google Scholar 

  33. Brown LF, Berse B, Jackman RW et al (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86–91

    Article  PubMed  CAS  Google Scholar 

  34. Gasparini G, Toi M, Gion M et al (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139–147

    Article  PubMed  CAS  Google Scholar 

  35. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Eng J Med 350:2335–2342

    Article  CAS  Google Scholar 

  36. Giantonio BJ, Meropol NJ, Catalano PJ et al (2007) Magnitude of progression-free survival improvement and treatment duration in metastatic colorectal cancer (mRC) for bevacizumab in combination with oxaliplatin-containing regimens: an analysis of two phase III studies. J Clin Oncol 25[Suppl 18]:4073

    Google Scholar 

  37. Cassidy J, Cunningham D, Berry SR et al (2008) Surgery with curative intent in patients treated with first line chemotherapy + bevacizumab for metastatic colorectal cancer (mCRC): first BEAT and NO 16966. J Clin Oncol 26[Suppl 15]: Abstract 4022

  38. Rothenberg ML, Cox JV, Butts C et al (2008) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19:1720–1726

    Article  PubMed  CAS  Google Scholar 

  39. Grothey A, Sugrue MM, Purdie DM et al (2008) Bevacizumab beyond first progression Is associated a with prolonged overall survival in metastatic colorectal cancer (BRiTE Study). J Clin Oncol 26:5326–5334

    Article  PubMed  CAS  Google Scholar 

  40. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799

    Article  PubMed  CAS  Google Scholar 

  41. Miller KD, Wang M, Gralow J et al (2007) A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab of first-line therapy for locally recurrent metastatic breast cancer. N Engl J Med 357:2666–2676

    Article  PubMed  CAS  Google Scholar 

  42. Milles D, Chang A, Romieu G et al (2008) Randomized, double-blind, placebo-controlled phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26[Suppl 15]: Abstract LBA1011

  43. Sandler A, Gray R, Perry M et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer. N Engl J Med 355:2542–2550

    Article  PubMed  CAS  Google Scholar 

  44. Manegold C, Von Pawel J, Zatluokal P et al (2007) Randomized, double-blind multicentre Phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non small-cell lung cancer. J Clin Oncol 25[Suppl]:S388 (Abst LBA 7514)

    Google Scholar 

  45. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, and anti-vascular endothelial growth factor antibody for metastatic renal cancer. N Engl J Med 349:427–434

    Article  PubMed  CAS  Google Scholar 

  46. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111

    Article  PubMed  Google Scholar 

  47. Escudier BJ, Ravaud A, Négrier S et al (2008) Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. J Clin Oncol 26[Suppl]: Abstract 5025

  48. Monk BJ, Han E, Josephs-Cowan CA et al (2006) Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 102:140–144

    Article  PubMed  CAS  Google Scholar 

  49. Burger RA, Sill MW, Monk BW et al (2007) Phase II trial of bevacizumab in persistentor recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 25:5165–5171

    Article  PubMed  CAS  Google Scholar 

  50. Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum resistant ovarian cancer or peritoneal cancer. J Clin Oncol 25:5180–5186

    Article  PubMed  CAS  Google Scholar 

  51. Garcia AA, Hirte H, Fleming G et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer. J Clin Oncol 26:76–81

    Article  PubMed  CAS  Google Scholar 

  52. Kaye SB (2007) Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J Clin Oncol 25:5150–5152

    Article  PubMed  CAS  Google Scholar 

  53. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729

    Article  PubMed  CAS  Google Scholar 

  54. Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787

    Article  PubMed  CAS  Google Scholar 

  55. Maron R, Vredenburgh JJ, Desjardins A et al (2008) Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). J Clin Oncol 26[Suppl]:Abstract 2074

  56. Malka D, Dromain C, Farace F et al (2007) Bevacizumab in patients with advanced hepatocellular carcinoma: preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol 25[Suppl]:4570

    Google Scholar 

  57. D’Adamo D, Anderson S, Albritton K et al (2005) Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 23:7135–7142

    Article  PubMed  Google Scholar 

  58. Fujita K, Sano D, Kimura M et al (2007) Antitumor effects of bevacizumab with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 18:47–51

    PubMed  CAS  Google Scholar 

  59. Kulke MH (2008) Neuroendocrine tumors: is there a standard treatment? Gastrointest Cancer Res 2:152–153

    PubMed  Google Scholar 

  60. Rini BI (2006) Sorafenib. Exp Opin Pharmacother 7:453–461

    Article  CAS  Google Scholar 

  61. Ratain MJ, Eisen T, Stadler WM (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512

    Article  PubMed  CAS  Google Scholar 

  62. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clearcell renal-cell carcinoma. N Engl J Med 356:125–134

    Article  PubMed  CAS  Google Scholar 

  63. Bukowski RM, Eisen T, Szczylik C et al (2007) Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 25[Suppl]:Abstract 5023

  64. Llovet J, Ricci S, Mazzaferro V et al (2007) Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 25:Abstract LBA1

  65. Azad N, Annunziata X, Perroy A et al (2008) Combination anti-angiogenesis therapy with sorafenib and bevacizumab in advanced solid tumors. Proceedings TAT 2008, plenary lecture 3, Bethesda, MD, March 20–22, 2008

  66. Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16–24

    Article  PubMed  CAS  Google Scholar 

  67. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884–896

    Article  PubMed  CAS  Google Scholar 

  68. Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516–2524

    Article  PubMed  CAS  Google Scholar 

  69. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124

    Article  PubMed  CAS  Google Scholar 

  70. George DJ, Michaelson MD, Rosenberg JE et al (2007) Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers. J Clin Oncol 25[Suppl]:Abstract 5053

  71. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335–348

    Article  PubMed  CAS  Google Scholar 

  72. Morgan B, Thomas AL, Drevs J et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–3964

    Article  PubMed  CAS  Google Scholar 

  73. Kim WY, Kaelin WG Jr (2006) Molecular pathways in renal cell carcinoma: rationale for targeted treatment. Semin Oncol 33:588–595

    Article  PubMed  CAS  Google Scholar 

  74. Muggia F (2008) Critical appraisal of antiangiogenesis: building on our successes. ESOC-5 Proceedings, Abs 7, The Oncologist.com

Download references

Author information

Authors and Affiliations

  1. Hospital Universitario 12 de Octubre, Avenida de Córdoba, s/n, ES-28041, Madrid, Spain

    Hernán Cortés-Funes

Authors
  1. Hernán Cortés-Funes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hernán Cortés-Funes.

Additional information

Presented in part as a Plenary Lecture at the XXV Anniversary of the Spanish Society for Cancer Research (ASEICA), Santiago de Compostela, 10 July 2008

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cortés-Funes, H. The role of antiangiogenesis therapy: Bevacizumab and beyond. Clin Transl Oncol 11, 349–355 (2009). https://doi.org/10.1007/s12094-009-0368-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-009-0368-0

Keywords

Search

Navigation